Printer Friendly

CAMBRIDGE NEUROSCIENCE AWARDED PHASE II SBIR GRANT TO FIND KILLER GENES AND FILES PATENT

 CAMBRIDGE NEUROSCIENCE AWARDED PHASE II SBIR GRANT TO
 FIND KILLER GENES AND FILES PATENT
 CAMBRIDGE, Mass., April 16 /PRNewswire/ -- Cambridge NeuroScience, Inc. (NASDAQ: CNSI) announced today that it has been awarded a Phase II Small Business Innovation Research grant of $500,000 to search for human equivalents of killer genes found in the roundworm, C. elegans. The killer genes, ced-3 and ced-4 are known to be involved in the biochemical pathway that results in the naturally occurring life-and-death cycle of nerve cells. The company has filed a patent to protect its proprietary interests in this area.
 Genetic analyses have demonstrated the key role these genes play in naturally occurring cell death. When the killer genes, ced-3 and ced-4, are mutated, cells that would normally die, instead survive. Compounds that prevent these killer genes from functioning could prevent nerve cells from dying. The company believes that the human equivalents of these genes are relevant targets of novel neuroprotective compounds which might be used to treat a variety of neurodegenerative diseases.
 "This NIH grant helps underwrite the cost of our discovery efforts and, in a very real sense, validates Cambridge NeuroScience's approach to this novel research," stated Elkan Gamzu, president and chief operating officer. "Cell death genetics is a long term program for Cambridge NeuroScience. This grant will serve to reinforce and accelerate the program. Cambridge NeuroScience has now successfully converted five of five Phase I SBIR grants to Phase II."
 Cambridge NeuroScience is a leading neuroscience company engaged in the discovery and development of proprietary pharmaceuticals with a focus on nerve cell survival. The company is developing a number of products to treat stroke, traumatic brain injury, schizophrenia and chronic neurodegenerative disorders such as diabetic peripheral neuropathy and amyotrophic lateral sclerosis (Lou Gehrig's disease).
 -0- 4/16/92
 /CONTACT: Elkan Gamzu, president and chief operating officer, 617-225-0600, ext. 116; or John T. Smith, manager of corporate communications, 617-225-0600 ext. 151, both of Cambridge NeuroScience/
 (CNSI) CO: Cambridge NeuroScience ST: Massachusetts IN: MTC SU:


TM -- NE001 -- 9165 04/16/92 10:14 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 16, 1992
Words:341
Previous Article:FLORIDA FIRST FEDERAL ANNOUNCES PROFIT FOR FIRST QUARTER 1992
Next Article:CONTINENTAL BANK CORPORATION REPORTS FIRST-QUARTER EARNINGS OF $57 MILLION


Related Articles
CAMBRIDGE NEUROSCIENCE GAINS ADDITIONAL NIH GRANT FOR STUDY OF COMPOUNDS TO PREVENT NEUROLOGICAL DAMAGE
CAMBRIDGE NEUROSCIENCE REPORTS FIRST QUARTER RESULTS
CEPHALON, INC. RECEIVES SBIR GRANT FROM THE NIH TO RESEARCH NOVEL THERAPEUTICS FOR BRAIN AND SPINAL CORD NERVE DAMAGE AND DEGENERATION
CAMBRIDGE NEUROSCIENCE AWARDED PHASE II SBIR GRANT FOR SIXTH TIME; GRANT AWARDED TO FURTHER RESEARCH IN ION-CHANNEL BLOCKERS
CELLEX BIOSCIENCES, INC. RECEIVES $500,000 GOVERNMENT GRANT FOR FURTHER DEVELOPMENT OF ITS OXYCELL BIOREACTOR
CAMBRIDGE NEUROSCIENCE RECEIVES U.S. PATENTS ON CERESTAT AND RELATED NEUROPROTECTIVE COMPOUNDS
ORAVAX RECEIVES SMALL BUSINESS INNOVATIVE RESEARCH GRANT FROM THE NATIONAL INSTITUTES OF HEALTH
Cambridge NeuroScience Awarded Phase I SBIR Grant for Development of Novel Agents to Reverse Nerve Damage
Cambridge NeuroScience Obtains Exclusive Rights to Neuregulin-2 Growth Factor From Harvard University.
Cambridge NeuroScience Awarded a Phase II SBIR Grant for Discovery of Drugs to Treat Peripheral Nerve Dysfunction.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters